


# Product Data Sheet

## XL-888

<b>Cat. No.:</b>	A4388
<b>CAS No.:</b>	1149705-71-4
<b>Formula:</b>	C29H37N5O3
<b>M.Wt:</b>	503.64
<b>Synonyms:</b>	XI 888, XI888
<b>Target:</b>	Metabolism
<b>Pathway:</b>	HSP
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

insoluble in H<sub>2</sub>O; insoluble in EtOH; ≥18.2 mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	1.9855 mL	9.9277 mL	19.8555 mL
	<b>5 mM</b>	0.3971 mL	1.9855 mL	3.9711 mL
	<b>10 mM</b>	0.1986 mL	0.9928 mL	1.9855 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

Hsp90 inhibitor

IC<sub>50</sub> & Target

24 nM (Hsp90)

In Vitro

### Cell Viability Assay

Cell Line:	Vemurafenib-resistant melanoma cell lines
Preparation method:	The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 °C for several months.
Reacting conditions:	300 nM; 72 or 144 hrs

	Applications:	In Vemurafenib-resistant melanoma cell lines, XL888 (300 nM) induced high levels (> 66%) of apoptosis and loss of mitochondrial membrane potential.
In Vivo	<b>Animal experiment</b>	
	Animal models:	Mice bearing M229R xenografts
	Dosage form:	100 mg/kg; p.o.; 3 times per week, for 15 days
	Applications:	XL888 (100 mg/kg) significantly induced the regression of established M229R xenografts in SCID mice.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

1. Azimi A, Caramuta S, et al. "Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors." Mol Syst Biol. 2018 Mar 5;14(3):e7858.PMID:29507054

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res. 2012; 18(9):2502-2514.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

**APEX BIO Technology**



[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

